Free Trial

Tourmaline Bio (TRML) Competitors

Tourmaline Bio logo
$19.68 -0.22 (-1.11%)
Closing price 06/13/2025 04:00 PM Eastern
Extended Trading
$19.68 +0.00 (+0.03%)
As of 06/13/2025 04:25 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

TRML vs. IDYA, BLTE, SDGR, INDV, GLPG, APGE, BEAM, IMCR, TARS, and BHC

Should you be buying Tourmaline Bio stock or one of its competitors? The main competitors of Tourmaline Bio include IDEAYA Biosciences (IDYA), Belite Bio (BLTE), Schrödinger (SDGR), Indivior (INDV), Galapagos (GLPG), Apogee Therapeutics (APGE), Beam Therapeutics (BEAM), Immunocore (IMCR), Tarsus Pharmaceuticals (TARS), and Bausch Health Companies (BHC). These companies are all part of the "pharmaceutical products" industry.

Tourmaline Bio vs. Its Competitors

Tourmaline Bio (NASDAQ:TRML) and IDEAYA Biosciences (NASDAQ:IDYA) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their valuation, institutional ownership, profitability, community ranking, earnings, media sentiment, dividends, risk and analyst recommendations.

IDEAYA Biosciences received 119 more outperform votes than Tourmaline Bio when rated by MarketBeat users. However, 96.00% of users gave Tourmaline Bio an outperform vote while only 71.86% of users gave IDEAYA Biosciences an outperform vote.

CompanyUnderperformOutperform
Tourmaline BioOutperform Votes
24
96.00%
Underperform Votes
1
4.00%
IDEAYA BiosciencesOutperform Votes
143
71.86%
Underperform Votes
56
28.14%

Tourmaline Bio's return on equity of -20.97% beat IDEAYA Biosciences' return on equity.

Company Net Margins Return on Equity Return on Assets
Tourmaline BioN/A -20.97% -20.56%
IDEAYA Biosciences N/A -26.74%-25.54%

Tourmaline Bio currently has a consensus target price of $49.33, indicating a potential upside of 150.68%. IDEAYA Biosciences has a consensus target price of $54.27, indicating a potential upside of 144.69%. Given Tourmaline Bio's stronger consensus rating and higher probable upside, research analysts plainly believe Tourmaline Bio is more favorable than IDEAYA Biosciences.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Tourmaline Bio
0 Sell rating(s)
0 Hold rating(s)
7 Buy rating(s)
0 Strong Buy rating(s)
3.00
IDEAYA Biosciences
0 Sell rating(s)
2 Hold rating(s)
11 Buy rating(s)
1 Strong Buy rating(s)
2.93

In the previous week, IDEAYA Biosciences had 1 more articles in the media than Tourmaline Bio. MarketBeat recorded 7 mentions for IDEAYA Biosciences and 6 mentions for Tourmaline Bio. Tourmaline Bio's average media sentiment score of 1.49 beat IDEAYA Biosciences' score of 0.98 indicating that Tourmaline Bio is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Tourmaline Bio
2 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
IDEAYA Biosciences
1 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

91.9% of Tourmaline Bio shares are owned by institutional investors. Comparatively, 98.3% of IDEAYA Biosciences shares are owned by institutional investors. 13.0% of Tourmaline Bio shares are owned by company insiders. Comparatively, 2.5% of IDEAYA Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Tourmaline Bio has higher earnings, but lower revenue than IDEAYA Biosciences. IDEAYA Biosciences is trading at a lower price-to-earnings ratio than Tourmaline Bio, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Tourmaline BioN/AN/A-$42.12M-$3.21-6.13
IDEAYA Biosciences$7M277.51-$274.48M-$3.59-6.18

Tourmaline Bio has a beta of 2.05, meaning that its share price is 105% more volatile than the S&P 500. Comparatively, IDEAYA Biosciences has a beta of 0.04, meaning that its share price is 96% less volatile than the S&P 500.

Summary

Tourmaline Bio beats IDEAYA Biosciences on 10 of the 17 factors compared between the two stocks.

Get Tourmaline Bio News Delivered to You Automatically

Sign up to receive the latest news and ratings for TRML and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding TRML and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

TRML vs. The Competition

MetricTourmaline BioBiological Products IndustryMedical SectorNASDAQ Exchange
Market Cap$505.48M$3.09B$5.57B$8.50B
Dividend YieldN/A1.56%5.27%4.17%
P/E Ratio-6.9832.6326.7519.66
Price / SalesN/A455.18403.98152.07
Price / CashN/A168.6838.2534.64
Price / Book1.953.366.964.59
Net Income-$42.12M-$72.35M$3.23B$248.23M
7 Day Performance2.13%0.36%-1.22%-1.07%
1 Month Performance26.80%16.10%6.34%2.59%
1 Year Performance16.04%-15.37%33.05%13.50%

Tourmaline Bio Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
TRML
Tourmaline Bio
2.8437 of 5 stars
$19.68
-1.1%
$49.33
+150.7%
+16.0%$505.48MN/A-6.9844Positive News
Analyst Revision
Gap Down
IDYA
IDEAYA Biosciences
3.8462 of 5 stars
$21.71
-0.1%
$54.27
+150.0%
-41.8%$1.90B$7M-6.5880Analyst Revision
Gap Down
BLTE
Belite Bio
2.6241 of 5 stars
$61.40
+2.9%
$96.67
+57.4%
+19.2%$1.90BN/A-55.3110Short Interest ↑
Analyst Revision
SDGR
Schrödinger
2.4778 of 5 stars
$25.47
+3.5%
$32.80
+28.8%
+3.9%$1.87B$230.49M-10.88790Gap Down
INDV
Indivior
2.5666 of 5 stars
$13.43
-4.5%
$15.00
+11.7%
-16.0%$1.85B$1.17B-38.371,164Positive News
GLPG
Galapagos
0.2604 of 5 stars
$28.09
+1.3%
$25.33
-9.8%
+13.1%$1.85B$288.19M0.001,310
APGE
Apogee Therapeutics
2.3868 of 5 stars
$40.13
-2.1%
$94.60
+135.7%
+8.1%$1.85BN/A-16.5891Positive News
Gap Down
BEAM
Beam Therapeutics
3.0763 of 5 stars
$18.17
-2.2%
$48.75
+168.3%
-31.4%$1.83B$63.58M-10.32510Analyst Revision
Gap Up
IMCR
Immunocore
3.0496 of 5 stars
$36.07
-3.2%
$58.89
+63.3%
-9.8%$1.81B$333.58M-37.97320Analyst Upgrade
Analyst Revision
High Trading Volume
TARS
Tarsus Pharmaceuticals
1.9143 of 5 stars
$43.11
-1.8%
$66.67
+54.6%
+32.0%$1.81B$233.67M-11.3150
BHC
Bausch Health Companies
3.9726 of 5 stars
$4.88
+2.5%
$7.42
+52.0%
-4.8%$1.81B$9.73B-40.6619,900News Coverage
Positive News
Insider Trade
Gap Up

Related Companies and Tools


This page (NASDAQ:TRML) was last updated on 6/15/2025 by MarketBeat.com Staff
From Our Partners